FY2025 EPS Estimates for AxoGen Boosted by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN) – Research analysts at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for shares of AxoGen in a report issued on Monday, March 31st. Leerink Partnrs analyst M. Kratky now expects that the medical equipment provider will post earnings of ($0.11) per share for the year, up from their previous estimate of ($0.12). The consensus estimate for AxoGen’s current full-year earnings is ($0.29) per share. Leerink Partnrs also issued estimates for AxoGen’s FY2026 earnings at $0.04 EPS, FY2028 earnings at $0.23 EPS and FY2029 earnings at $0.34 EPS.

Several other research firms have also issued reports on AXGN. Lake Street Capital began coverage on shares of AxoGen in a research note on Monday, March 17th. They issued a “buy” rating and a $30.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 price target on shares of AxoGen in a research report on Wednesday, March 5th. Finally, Canaccord Genuity Group upped their price target on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $22.60.

AxoGen Price Performance

NASDAQ AXGN opened at $17.69 on Wednesday. The company has a quick ratio of 2.47, a current ratio of 3.74 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $784.45 million, a PE ratio of -55.28 and a beta of 1.02. AxoGen has a 12-month low of $5.55 and a 12-month high of $21.00. The company has a 50 day moving average price of $18.23 and a two-hundred day moving average price of $15.94.

Insider Activity at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 5,000 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $20.02, for a total transaction of $100,100.00. Following the completion of the sale, the director now owns 97,899 shares in the company, valued at approximately $1,959,937.98. The trade was a 4.86 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Erick Wayne Devinney sold 15,111 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $17.50, for a total value of $264,442.50. Following the completion of the transaction, the insider now directly owns 217,762 shares in the company, valued at approximately $3,810,835. This trade represents a 6.49 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On AxoGen

A number of institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC boosted its holdings in AxoGen by 10.2% during the fourth quarter. First Light Asset Management LLC now owns 4,506,795 shares of the medical equipment provider’s stock worth $74,272,000 after buying an additional 416,499 shares during the last quarter. Geode Capital Management LLC grew its holdings in AxoGen by 3.2% during the third quarter. Geode Capital Management LLC now owns 1,010,508 shares of the medical equipment provider’s stock valued at $14,170,000 after purchasing an additional 31,612 shares during the period. Driehaus Capital Management LLC grew its holdings in AxoGen by 166.0% during the fourth quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider’s stock valued at $15,729,000 after purchasing an additional 595,579 shares during the period. State Street Corp increased its stake in AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider’s stock valued at $12,571,000 after purchasing an additional 95,051 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in AxoGen by 13.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 772,752 shares of the medical equipment provider’s stock worth $12,735,000 after purchasing an additional 91,984 shares during the period. 80.29% of the stock is owned by institutional investors and hedge funds.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.